查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591980

免疫腫瘤學市場：按類型、適應症和最終用戶分類 - 全球預測 2025-2030

Immuno-Oncology Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年免疫腫瘤市值為53.6億美元，預計2024年將達到58.9億美元，複合年成長率為9.99%，到2030年將達到104.5億美元。

免疫腫瘤學是一個快速發展的領域，專注於利用人體的免疫系統來對抗癌症。它包括旨在提高癌症患者的生存率和生活品質的各種治療方法，例如免疫查核點抑制劑、癌症疫苗和細胞療法。免疫腫瘤學的需求源於傳統癌症治療的局限性，例如化療，通常會引起嚴重的副作用，並且控制疾病的效果有限。該領域旨在提供有針對性的干涉措施，激活特異性針對癌細胞的免疫反應，為癌症治療提供一種有前途的替代方案。免疫腫瘤學有廣泛的應用，從治療各種癌症類型（如黑色素瘤、肺癌和大腸癌）到提高療效的聯合治療。最終用途範圍主要針對醫院、癌症研究中心和專科診所。

主要市場統計
基準年[2023] 53.6億美元
預測年份 [2024] 58.9億美元
預測年份 [2030] 104.5億美元
複合年成長率（%） 9.99%

免疫腫瘤學市場受到癌症發生率增加、生物技術進步以及對腫瘤免疫學了解加深等因素的影響。對個人化醫療的需求不斷成長以及對研發的持續關注將進一步推動市場成長。然而，某些癌症的治療成本高、監管途徑複雜以及患者反應有限等挑戰構成了重大障礙。儘管面臨這些挑戰，該領域仍存在利潤豐厚的商機，包括開發用於患者分層的新型生物標記、提高聯合治療的療效以及擴大細胞療法的應用等。創新比比皆是，例如探索雙特異性抗體、提高 T 細胞療法的功效以及利用人工智慧進行藥物發現和開發。

為了抓住這些機會，相關人員應專注於合作研究、與生技公司的策略聯盟以及對新興技術的投資。此外，解決與成本相關的挑戰和改善患者獲得治療的機會仍然至關重要。市場動態是充滿活力和競爭的，其特點是技術快速進步和對臨床試驗的重視。持續創新和策略適應不斷變化的科學見解和市場需求對於這個變革領域的持續成長和成功至關重要。

市場動態：揭示快速發展的免疫腫瘤學市場的關鍵市場洞察

供需的動態交互作用正在改變免疫腫瘤學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症患者數量增加
    • 政府積極主動控制癌症
    • 人們越來越偏好免疫療法和標靶治療
  • 市場限制因素
    • 與免疫腫瘤學相關的高額醫療費用
  • 市場機會
    • 研究開發活動資金籌措快速增加
    • 擴大個人化醫療和精準腫瘤學
  • 市場挑戰
    • 對免疫腫瘤學對健康的負面影響的擔憂

波特五力：駕馭免疫腫瘤學市場的策略工具

波特的五力框架是了解免疫腫瘤學市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解免疫腫瘤學市場的外部影響

外部宏觀環境因素在塑造免疫腫瘤學市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解免疫腫瘤學市場的競爭格局

免疫腫瘤學市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣免疫腫瘤學市場供應商的績效評估

FPNV定位矩陣是評估免疫腫瘤市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了免疫腫瘤學市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，免疫腫瘤學市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症患者的負擔不斷增加
      • 政府首選的癌症控制方法
      • 人們對免疫療法和標靶治療的興趣日益濃厚
    • 抑制因素
      • 與免疫腫瘤學相關的高額醫療費用
    • 機會
      • 研究開發活動經費快速增加
      • 擴大個人化醫療和精準腫瘤學
    • 任務
      • 對免疫腫瘤學對健康的負面影響的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章免疫腫瘤學市場：依類型

  • 癌症疫苗
  • 查核點抑制劑
  • 細胞激素
  • 免疫細胞療法（CAR-T）
  • 單株抗體

第7章依適應症分類的免疫腫瘤學市場

  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 惡性黑色素瘤

第8章免疫腫瘤學市場：依最終用戶分類

  • 學術/研究機構
  • 醫院/診所

第 9 章：美洲免疫腫瘤學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太免疫腫瘤市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的免疫腫瘤市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Agilent Technologies, Inc.
  • Allogene Therapeutics
  • Amgen Inc.
  • Arcus Biosciences, Inc.
  • Asher Biotherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • Avantor, Inc.
  • BeiGene, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Cellectis SA
  • F. Hoffmann-La Roche AG
  • Fate Therapeutics Inc.
  • Merck KGaA
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Triumvira Immunologics Inc.
Product Code: MRR-FF012EDC38BF

The Immuno-Oncology Market was valued at USD 5.36 billion in 2023, expected to reach USD 5.89 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 10.45 billion by 2030.

Immuno-oncology is a rapidly advancing field focusing on harnessing the body's immune system to fight cancer. Its scope involves various therapies, such as immune checkpoint inhibitors, cancer vaccines, and cell therapies, which aim to improve survival rates and quality of life for cancer patients. The necessity of immuno-oncology stems from the limitations of traditional cancer therapies, such as chemotherapy, which often result in severe side effects and limited efficacy in controlling the disease. This field aims to provide targeted interventions that activate an immune response specifically against cancer cells, offering a promising alternative for cancer treatment. Applications of immuno-oncology span from treating various cancer types, including melanoma, lung, and colorectal cancers, to combination therapies that enhance effectiveness. The end-use scope primarily targets hospitals, cancer research centers, and specialized clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.36 billion
Estimated Year [2024] USD 5.89 billion
Forecast Year [2030] USD 10.45 billion
CAGR (%) 9.99%

The market for immuno-oncology is influenced by factors such as increased cancer prevalence, advancements in biotechnology, and improved understanding of tumor immunology. The rising demand for personalized medicine and the ongoing focus on R&D further propel market growth. However, challenges such as high treatment costs, complex regulatory pathways, and limited patient response in certain cancers pose significant hurdles. Despite these challenges, the field presents lucrative opportunities, particularly in developing novel biomarkers for patient stratification, enhancing the efficacy of combinatory therapies, and expanding the application of cell therapies. Innovations abound in exploring bispecific antibodies, enhancing T-cell therapy effectiveness, and leveraging AI for drug discovery and development.

To seize these opportunities, stakeholders should focus on collaborative research efforts, strategic partnerships with biotechnology firms, and investments in emerging technologies. Additionally, addressing cost-related challenges and improving patient access to therapies remain crucial. The nature of the immuno-oncology market is dynamic and highly competitive, characterized by rapid technological advancements and a strong emphasis on clinical trials. Continued innovation and strategic adaptation to evolving scientific insights and market demands are essential for sustained growth and success in this transformative field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immuno-Oncology Market

The Immuno-Oncology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing burden of cancer cases across the globe
    • Favorable government initiatives for cancer management
    • Growing preference for immunotherapy and targeted therapies
  • Market Restraints
    • Associated high medical expenses of immuno-oncology
  • Market Opportunities
    • Surge in fundings for research and development activities
    • Expansion of personalized medicine and precision oncology
  • Market Challenges
    • Concern regarding adverse health impacts of immuno-oncology

Porter's Five Forces: A Strategic Tool for Navigating the Immuno-Oncology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immuno-Oncology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immuno-Oncology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immuno-Oncology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immuno-Oncology Market

A detailed market share analysis in the Immuno-Oncology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immuno-Oncology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immuno-Oncology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immuno-Oncology Market

A strategic analysis of the Immuno-Oncology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno-Oncology Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Agilent Technologies, Inc., Allogene Therapeutics, Amgen Inc., Arcus Biosciences, Inc., Asher Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, Avantor, Inc., BeiGene, Inc., Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cellectis SA, F. Hoffmann-La Roche AG, Fate Therapeutics Inc., Merck KGaA, Sanofi S.A., Thermo Fisher Scientific Inc., and Triumvira Immunologics Inc..

Market Segmentation & Coverage

This research report categorizes the Immuno-Oncology Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cancer Vaccines, Checkpoint Inhibitors, Cytokines, Immune Cell Therapy (CAR-T), and Monoclonal Antibodies.
  • Based on Indication, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Melanoma.
  • Based on End-Users, market is studied across Academic & Research Institutions and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing burden of cancer cases across the globe
      • 5.1.1.2. Favorable government initiatives for cancer management
      • 5.1.1.3. Growing preference for immunotherapy and targeted therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Associated high medical expenses of immuno-oncology
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in fundings for research and development activities
      • 5.1.3.2. Expansion of personalized medicine and precision oncology
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding adverse health impacts of immuno-oncology
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immuno-Oncology Market, by Type

  • 6.1. Introduction
  • 6.2. Cancer Vaccines
  • 6.3. Checkpoint Inhibitors
  • 6.4. Cytokines
  • 6.5. Immune Cell Therapy (CAR-T)
  • 6.6. Monoclonal Antibodies

7. Immuno-Oncology Market, by Indication

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Lung Cancer
  • 7.5. Melanoma

8. Immuno-Oncology Market, by End-Users

  • 8.1. Introduction
  • 8.2. Academic & Research Institutions
  • 8.3. Hospitals & Clinics

9. Americas Immuno-Oncology Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Immuno-Oncology Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Immuno-Oncology Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Adicet Bio, Inc.
  • 4. Agilent Technologies, Inc.
  • 5. Allogene Therapeutics
  • 6. Amgen Inc.
  • 7. Arcus Biosciences, Inc.
  • 8. Asher Biotherapeutics, Inc.
  • 9. Astellas Pharma Inc.
  • 10. AstraZeneca PLC
  • 11. Atara Biotherapeutics, Inc.
  • 12. Autolus Therapeutics PLC
  • 13. Avantor, Inc.
  • 14. BeiGene, Inc.
  • 15. Bio-Rad Laboratories, Inc.
  • 16. BioNTech SE
  • 17. Boehringer Ingelheim International GmbH
  • 18. Bristol Myers Squibb
  • 19. Cellectis SA
  • 20. F. Hoffmann-La Roche AG
  • 21. Fate Therapeutics Inc.
  • 22. Merck KGaA
  • 23. Sanofi S.A.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Triumvira Immunologics Inc.

LIST OF FIGURES

  • FIGURE 1. IMMUNO-ONCOLOGY MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNO-ONCOLOGY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNO-ONCOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNO-ONCOLOGY MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY IMMUNE CELL THERAPY (CAR-T), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2023